← All trials
NCT04931368
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2021
- Primary completion
- Aug 31, 2027
- Completion date
- May 31, 2028
- First posted
- Jun 18, 2021
- Last posted
- Jun 22, 2021
- Enrollment
- 326
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TuebingenLead sponsor
- University of FreiburgCollaborator
- University of TuebingenOverall official - principal investigator
- German Federal Ministry of Education and ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.